Technical Articles

FGFR4 (fibroblast growth factor receptor 4) is an important member of the receptor tyrosine kinase family, and its signaling pathway plays a key role in regulating cell proliferation, differentiation and immune response. In recent years, the predictive value of FGFR4 mutation in immunotherapy of non-small cell lung cancer (NSCLC) has gradually attracted attention. Many studies have shown that FGFR4 mutation is not only significantly associated with the efficacy of immunotherapy, but also affects the treatment response by reshaping the tumor immune microenvironment, providing a new molecular target for optimizing immunotherapy strategies.